Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
120

Summary

Conditions
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lymphoma, B Cell
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Richter's Transformation
  • Small Lymphocytic Lymphoma
  • Waldenstrom Macroglobulinemia
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Single Group AssignmentIntervention Model Description: Single group assignment (definition : A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment.)Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, patients were enrolled using 3+3 dose escalation design. The starting dose of ARQ 531 in oral tablet form was 5mg/day continuously. The RP2D has been determined at 65mg/day, patients will be enrolled to ...

This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, patients were enrolled using 3+3 dose escalation design. The starting dose of ARQ 531 in oral tablet form was 5mg/day continuously. The RP2D has been determined at 65mg/day, patients will be enrolled to one of 8 cohorts depending on tumor histology and prior treatment history. Cycle length will be 28 days.

Tracking Information

NCT #
NCT03162536
Collaborators
Not Provided
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.